Loading…
Loading…
COSTA MESA, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today announced that it plans to release the Company's 2026 third quarter financial results on November 5, 2026, prior to the stock market opening. Stephen G. Oswald, the Company's chairman, president and chief executive officer, and Suman Mookerji, the Company's senior vice president and chief financial officer, will host a call that day at 10:00 a.m. PT (1:00 p.m. ET) to review these results.
COSTA MESA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) hosted its first Investor Day event in nearly four years.
Here is how Ducommun (DCO) and Lockheed Martin (LMT) have performed compared to their sector so far this year.
Ducommun remains a Buy as Vision 2032 targets 7-8% organic growth, a 23% EBITDA margin, and a larger Engineered Products mix. DCO's investment case now leans on defense and proprietary products, with commercial aerospace recovery and missile/radar programs driving incremental demand. Valuation upside depends on EV/EBITDA multiple expansion toward peers; the new price target is $216.50, reflecting improved estimates but lower sector multiples.
Ducommun Incorporated (DCO) Analyst/Investor Day Transcript
COSTA MESA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) a global supplier of Engineered Products, Aftermarket and Value-Added Manufacturing Solutions for the aerospace and defense industry, is proud to announce that it has been awarded an agreement from Simmonds Precision Products, Inc. (“Simmonds”) to provide electronic assemblies supporting Lockheed Martin's (NYSE: LMT) PAC-3 family of missiles.
California State Teachers Retirement System grew its stake in Ducommun Incorporated (NYSE: DCO) by 15,792.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,858,346 shares of the aerospace company's stock after acquiring an additional 2,840,361 shares during the period. California State Teachers Retirement System
Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSOÂ (osimertinib) demonstrated a sustained, clinically meaningful overal